The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 18.00
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.778%)
Open: 18.25
High: 18.25
Low: 18.25
Prev. Close: 18.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert Joins River & Mercantile

Wed, 06th Jan 2021 14:27

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and not separately reported by Alliance News:

----------

River & Mercantile Group PLC - Hires Martin Gilbert to be deputy chair, starting Wednesday. Gilbert was the co-founder and then chief executive of Aberdeen Asset Management, now Standard Life Aberdeen PLC. He currently is chair of lender Revolut Ltd and senior independent director of miner Glencore PLC. "In the current environment there are market opportunities for RMG, both organic and through acquisitions, that can drive shareholder value," Gilbert says. River & Mercantile had GBP45.4 billion in assets under management as of September 30.

----------

Fulcrum Utility Services Ltd - Sheffield-based multi-utility infrastructure and services provider - Daren Harris steps down as chief executive officer and from board, effective immediately. Chief Operating Officer Terry Dugdale, in post since March 2019, becomes CEO. "The business is well placed with strong market drivers and a robust balance sheet and its strategy is strongly positioned to capitalise on the UK's journey to net zero," Harris says. "Unfortunately, due to personal reasons, I need to step down from the business." He adds: "Since joining the business, Terry has driven our operating efficiency and has made significant progress in preparing the business foundations for the future."

----------

Silence Therapeutics PLC - London-based novel short interfering ribonucleic acid therapeutics developer - Hires Craig Tooman as chief financial officer, effective immediately. Tooman was most recently CFO & COO of Princeton, New Jersey-based Vyome Therapeutic Inc. Silence also says Michael Davidson has joined the Silence board as non-executive director. Davidson currently is CEO of New Amsterdam Pharma BV and a professor of medicine at the Lipid Clinic at the University of Chicago. He founded Omthera Pharmaceuticals in 2008, which was acquired by AstraZeneca PLC in 2013, and was founding CEO of Corvidia Therapeutics, which was acquired by Novo Nordisk AS in 2020.

----------

Personal Group Holdings PLC - Milton Keynes, Buckinghamshire-based provider of employee services - Makes Interim CFO Sarah Mace its permanent CFO, effective immediately. Mace was promoted to the board as interim CFO back in October, having joined Personal Group in 2014.

----------

Kape Technologies PLC - Isle of Man-based digital security and privacy software company - Hires Pierre-Etienne Lallia as non-executive director, effective immediately. Lallia spent 10 years at Nomura International PLC in London, where he was managing director of the Acquisition & Leveraged Finance team. Prior to that, he was with Goldman Sachs International, part of Goldman Sachs Group Inc.

----------

Time Finance PLC - Bath, England-based finance provider to UK small and medium businesses - Non-Executive Chair John Newman and CEO Ian Smith both to retire once successors are found. Says process for replacing the pair is underway. Says Smith's decision follows rebranding of company from 1pm PLC early last month and his previous intention to retire in any event at the end of 2021.

----------

Destiny Pharma PLC - Brighton-based clinical stage biotechnology firm focused on preventing infections - Hires Stephanie Bewick as chief business officer. Bewick was vice president for Business Development at Nasdaq-listed Summit Therapeutics Inc.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2019 16:06

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Read more
2 Dec 2019 15:57

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Read more
16 Oct 2019 14:48

Destiny Pharma pleased with latest XF-73 results at it proceeds with next phase

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma reported on the publication of results from a positive phase 1 clinical study in 60 healthy United States volunteers using a nasal gel formulation of its lead drug, XF-73 (exeporfinium chloride), on Wednesday.

Read more
16 Oct 2019 11:36

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Read more
23 Sep 2019 16:09

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Read more
23 Sep 2019 12:12

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Read more
10 Sep 2019 14:16

Destiny Pharma Collaboration With University Of Sheffield Wins Funding

(Alliance News) - Destiny Pharma PLC on Tuesday said it has been awarded a grant along with the University of Sheffield for their research collaboration on drug-resistant infections.Shares

Read more
9 Apr 2019 11:17

Destiny Pharma Annual Loss Doubles On Higher Costs, Confident Outlook

LONDON (Alliance News) - Destiny Pharma PLC on Tuesday reported a significantly widened annual loss as expenses surged in the run-up to the development of its lead candidate.For 2018, the a

Read more
9 Apr 2019 09:32

Destiny Pharma 'well funded' despite wider loss

(Sharecast News) - Destiny Pharma on Tuesday reported a wider annual loss as it increased research and development costs, although the company is "well funded" through to the second half of next year.

Read more
2 Apr 2019 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 3 April AAFull Year ResultsCMC MarketsTrading GroupTrading Year Year 4

Read more
27 Mar 2019 11:53

Destiny Pharma, MedPharm To Develop New XF-Platform Drug Formulations

LONDON (Alliance News) - Destiny Pharma PLC on Wednesday said it has partnered with MedPharm to develop new formulations of its XF-platform compounds.MedPharm is a contract provider of and

Read more
28 Jan 2019 11:46

Destiny Pharma Gets Positive Results From Second Phase Trial Of XF-73

LONDON (Alliance News) - Destiny Pharma PLC on Monday reported positive results in a second phase 1 clinical study examining the anti-irritation features of its XF-73 nasal gel.The study, a

Read more
28 Jan 2019 10:39

Destiny Pharma sees success in latest trial of XF-73 nasal gel

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive data and the non-irritant classification for its XF-73 nasal gel on Monday.

Read more
25 Jan 2019 10:58

Destiny Pharma leaps on £1.6m grant and UK-China collaboration

(Sharecast News) - Destiny Pharma jumped on Friday after being awarded funding of up to £1.6m from a collaboration established under the UK-China AMR grant fund.

Read more
25 Jan 2019 09:53

Destiny Pharma Gets Funding For Antimicrobial Resistance Research

LONDON (Alliance News) - Destiny Pharma PLC said Friday that it has secured a GBP1.6 million grant for examining novel drugs to prevent, control and eradicate life threatening bacteria or without

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.